These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

173 related articles for article (PubMed ID: 27142144)

  • 1. From organophosphate poisoning to diabetes mellitus: The incretin effect.
    Rathish D; Agampodi SB; Jayasumana MACS; Siribaddana SH
    Med Hypotheses; 2016 Jun; 91():53-55. PubMed ID: 27142144
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A low GLP-1 response among patients treated for acute organophosphate and carbamate poisoning: a comparative cross-sectional study from an agrarian region of Sri Lanka.
    Rathish D; Senavirathna I; Jayasumana C; Agampodi S; Siribaddana S
    Environ Sci Pollut Res Int; 2019 Jan; 26(3):2864-2872. PubMed ID: 30499084
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The incretin system and its role in type 2 diabetes mellitus.
    Holst JJ; Vilsbøll T; Deacon CF
    Mol Cell Endocrinol; 2009 Jan; 297(1-2):127-36. PubMed ID: 18786605
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Physiology of incretins and loss of incretin effect in type 2 diabetes and obesity.
    Opinto G; Natalicchio A; Marchetti P
    Arch Physiol Biochem; 2013 Oct; 119(4):170-8. PubMed ID: 23859800
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of the incretin pathway in the pathogenesis of type 2 diabetes mellitus.
    Freeman JS
    Cleve Clin J Med; 2009 Dec; 76 Suppl 5():S12-9. PubMed ID: 19952298
    [TBL] [Abstract][Full Text] [Related]  

  • 6. GIP: no longer the neglected incretin twin?
    Kulkarni RN
    Sci Transl Med; 2010 Sep; 2(49):49ps47. PubMed ID: 20844284
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Focus on incretin-based therapies: targeting the core defects of type 2 diabetes.
    Jellinger PS
    Postgrad Med; 2011 Jan; 123(1):53-65. PubMed ID: 21293084
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Diabetes mellitus and osteoporosis. Incretin as a coordinator of glucose and bone metabolism].
    Yamada Y
    Clin Calcium; 2012 Sep; 22(9):1353-8. PubMed ID: 22932289
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Incretin hormones and beta cell function in chronic pancreatitis.
    Knop FK
    Dan Med Bull; 2010 Jul; 57(7):B4163. PubMed ID: 20591345
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Incretin effect: GLP-1, GIP, DPP4.
    Kazafeos K
    Diabetes Res Clin Pract; 2011 Aug; 93 Suppl 1():S32-6. PubMed ID: 21864749
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Incretin mimetics and dipeptidyl peptidase-IV inhibitors: potential new therapies for type 2 diabetes mellitus.
    Triplitt C; Wright A; Chiquette E
    Pharmacotherapy; 2006 Mar; 26(3):360-74. PubMed ID: 16503716
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Glucagon-like peptide-1, glucose homeostasis and diabetes.
    Holst JJ; Deacon CF; Vilsbøll T; Krarup T; Madsbad S
    Trends Mol Med; 2008 Apr; 14(4):161-8. PubMed ID: 18353723
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The role of incretin on diabetes mellitus.
    Sanusi H
    Acta Med Indones; 2009 Oct; 41(4):205-12. PubMed ID: 20737753
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiating incretin therapies based on structure, activity, and metabolism: focus on liraglutide.
    Grossman S
    Pharmacotherapy; 2009 Dec; 29(12 Pt 2):25S-32S. PubMed ID: 19947814
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Novel incretin-based agents and practical regimens to meet needs and treatment goals of patients with type 2 diabetes mellitus.
    Garber AJ
    J Am Osteopath Assoc; 2011 Jul; 111(7 Suppl 5):S20-30. PubMed ID: 21813733
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Regulation of glucagon secretion by incretins.
    Holst JJ; Christensen M; Lund A; de Heer J; Svendsen B; Kielgast U; Knop FK
    Diabetes Obes Metab; 2011 Oct; 13 Suppl 1():89-94. PubMed ID: 21824261
    [TBL] [Abstract][Full Text] [Related]  

  • 17. [Incretin hormones in the treatment of type 2 diabetes. Part I: influence of insulinotropic gut-derived hormones (incretins) on glucose metabolism].
    Matuszek B; Lenart-Lipińska M; Nowakowski A
    Endokrynol Pol; 2007; 58(6):522-8. PubMed ID: 18205109
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Minireview: update on incretin biology: focus on glucagon-like peptide-1.
    Brubaker PL
    Endocrinology; 2010 May; 151(5):1984-9. PubMed ID: 20305008
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Predictors of incretin concentrations in subjects with normal, impaired, and diabetic glucose tolerance.
    Vollmer K; Holst JJ; Baller B; Ellrichmann M; Nauck MA; Schmidt WE; Meier JJ
    Diabetes; 2008 Mar; 57(3):678-87. PubMed ID: 18057091
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Small intestinal glucose exposure determines the magnitude of the incretin effect in health and type 2 diabetes.
    Marathe CS; Rayner CK; Bound M; Checklin H; Standfield S; Wishart J; Lange K; Jones KL; Horowitz M
    Diabetes; 2014 Aug; 63(8):2668-75. PubMed ID: 24696447
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.